EHA 2021 | The Beat AML Trial: precision medicine in AML
John Byrd
• 3 Jun 2021
John Byrd, MD, Ohio State University, Columbus, OH, talks on the incorporation and impact of whole genome sequencing into the treatment and management of acute myeloid leukemia (AML), commenting on the findings of the Beat AML Trial (NCT03013998). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
John Byrd, MD, has received honoraria from AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium Therapeutics; has participated in a consultancy or advisory role for Acerta Pharma, Genentech, Pharmacyclics and Jazz Pharmaceuticals; and has received research funding from Acerta Pharma and Pharmacyclics.
